March 9, 2020
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating new side effect risks for five medicines including Shionogi’s novel influenza med Xofluza (baloxavir marboxil) and MSD’s anti-PD-1 antibody Keytruda (pembrolizumab), a move likely to trigger a label change in the...read more